SCHEMBL6597900

SCHEMBL6597900

COCCN1c2ccc([N+](=O)[O-])cc2CS1(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
WDR5 P61964 6/20 0.40
KDM4E B2RXH2 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SNCA P37840 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
CASP1 P29466 1/20 0.38
CASP3 P42574 1/20 0.38
CASP4 P49662 1/20 0.38
CASP7 P55210 1/20 0.38
CASP9 P55211 1/20 0.38
CASP6 P55212 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6593532 0.83 SIRT2 (0.40) ALDH1A1WDR5SIRT2SMN1; SMN2LMNA
SCHEMBL13234005 0.82 BMPR1B (0.45) ALDH1A1SIRT2SMN1; SMN2LMNAHTT
SCHEMBL6594993 0.78 LMNA (0.48) ALDH1A1WDR5SIRT2SMN1; SMN2LMNA
SCHEMBL6593277 0.76 ALDH1A1 (0.44) ALDH1A1SIRT2SMN1; SMN2LMNAKMT2A
SCHEMBL16391111 0.75 MAPT (0.55) ALDH1A1WDR5KDM4ESIRT2SMN1; SMN2
SCHEMBL30672818 0.75 MAPT (0.55) ALDH1A1WDR5KDM4ESIRT2SMN1; SMN2
SCHEMBL30672820 0.74 GAA (0.48) ALDH1A1SIRT2SMN1; SMN2SNCALMNA
SCHEMBL16370713 0.74 GAA (0.48) ALDH1A1SIRT2SMN1; SMN2SNCALMNA
SCHEMBL18421420 0.73 GRIN1 (0.51) ALDH1A1SIRT2SMN1; SMN2LMNAHTT
SCHEMBL16370521 0.73 DPP7 (0.45) ALDH1A1SMN1; SMN2LMNAHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268475-B1 NOVEL BENZOSULTAM OXAZOLIDINONE ANTIBACTERIAL AGENTS UPJOHN CO (US) 2004-09-22 EP disclosed
EP-1268475-A1 NOVEL BENZOSULTAM OXAZOLIDINONE ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-01-02 EP disclosed
US-6365612-B2 Benzosultam oxazolidinone antibacterial agents PHARMACIA & UPJOHN COMPANY 2002-04-02 US disclosed
US-20010047018-A1 Novel benzosultam oxazolidinone antibacterial agents PHARMACIA & UPJOHN COMPANY 2001-11-29 US disclosed
WO-2001074812-A1 NOVEL BENZOSULTAM OXAZOLIDINONE ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047018-A1 Novel benzosultam oxazolidinone antibacterial agents OXA1L, TUFM, MRPL21 ALDH1A1 459/4885WDR5 304/4885KDM4E 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.